Coherus Oncology, Inc. (CHRS)

Coherus Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	277.73	266.96	257.24	211.04	326.55	475.82
Revenue	277.73	266.96	257.24	211.04	326.55	475.82
Revenue Growth (YoY)	152.07%	3.78%	21.89%	-35.37%	-31.37%	33.63%
Cost of Revenue	121.35	117.55	158.99	70.08	57.59	37.67
Gross Profit	156.38	149.41	98.25	140.96	268.96	438.16
Selling, General & Admin	140.06	150.44	185.62	198.48	169.71	139.08
Research & Development	100.18	93.34	105.84	199.36	363.11	142.76
Operating Expenses	240.24	243.77	291.45	397.84	532.82	281.84
Operating Income	-83.85	-94.37	-193.2	-256.88	-263.86	156.32
Interest Expense	-25.09	-27.16	-40.54	-32.47	-22.96	-21.17
Interest & Investment Income	4.5	4.5	2.8	1.9	1.4	0.6
Other Non Operating Income (Expenses)	-2.32	-1.13	2.67	1.92	-1.68	-0.05
EBT Excluding Unusual Items	-106.76	-118.15	-228.27	-285.53	-287.1	135.71
Merger & Restructuring Charges	-6.7	-6.7	-10	-	-	-
Gain (Loss) on Sale of Assets	176.59	176.59	-	-	-	-
Asset Writedown	-2.1	-10.6	-	-	-	-
Other Unusual Items	-	-12.63	-	-6.22	-	-
Pretax Income	61.03	28.51	-238.27	-291.75	-287.1	135.71
Income Tax Expense	-	-	-0.38	-	-	3.46
Earnings From Continuing Operations	61.03	28.51	-237.89	-291.75	-287.1	132.24
Net Income	154.97	28.51	-237.89	-291.75	-287.1	132.24
Net Income to Common	154.97	28.51	-237.89	-291.75	-287.1	132.24
Net Income Growth	-	-	-	-	-	47.21%
Shares Outstanding (Basic)	116	115	94	78	75	71
Shares Outstanding (Diluted)	116	115	94	78	75	83
Shares Change (YoY)	2.22%	21.95%	21.30%	2.89%	-9.63%	14.08%
EPS (Basic)	1.34	0.25	-2.53	-3.76	-3.81	1.85
EPS (Diluted)	1.34	0.25	-2.53	-3.76	-3.81	1.62
EPS Growth	-	-	-	-	-	31.99%
Free Cash Flow	-90.19	-20.44	-174.88	-241.12	-38.72	146.91
Free Cash Flow Per Share	-0.78	-0.18	-1.86	-3.11	-0.51	1.76
Gross Margin	56.31%	55.97%	38.19%	66.79%	82.36%	92.08%
Operating Margin	-30.19%	-35.35%	-75.10%	-121.72%	-80.80%	32.85%
Profit Margin	55.80%	10.68%	-92.48%	-138.25%	-87.92%	27.79%
Free Cash Flow Margin	-32.47%	-7.66%	-67.98%	-114.25%	-11.86%	30.88%
EBITDA	-79.79	-89.09	-189.41	-253.18	-260.4	159.21
EBITDA Margin	-28.73%	-33.37%	-73.63%	-119.97%	-79.74%	33.46%
D&A For EBITDA	4.06	5.28	3.79	3.7	3.45	2.89
EBIT	-83.85	-94.37	-193.2	-256.88	-263.86	156.32
EBIT Margin	-30.19%	-35.35%	-75.10%	-121.72%	-80.80%	32.85%
Effective Tax Rate	-	-	-	-	-	2.55%
Advertising Expenses	-	10.9	10.9	10.5	-	3.8

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q